LEDGER STEVEN A 4

What Happened Steven A. Ledger, Chief Executive Officer of Serina Therapeutics (SER), received a grant/award of derivative securities covering 380,825 shares on 2026-05-21. The filing shows an acquisition price of $0.00 (no cash paid at grant), consistent with an options award rather than an open‑market purchase or sale.

Key Details

• Transaction type: Grant/Award (derivative securities, transaction code A)
• Transaction date: 2026-05-21; Form 4 filed 2026-05-26 (timely)
• Shares/units granted: 380,825 (acquisition price listed as $0.00)
• Shares owned after transaction: Not specified in the provided filing summary
• Notable footnote: Vesting described in footnote F1 — 12/48ths vest 12 months after the Vesting Commencement Date (one‑year cliff), then 1/48th vests each month thereafter until fully vested (i.e., typical four‑year schedule)
• No immediate sale or cashless exercise reported

Context This is a compensation-related option award for the CEO, not a market purchase or sale. Option grants do not necessarily indicate a near‑term market signal — they create potential future upside if the company’s stock appreciates and the options are exercised according to the vesting and exercise terms.